Norifaz (Risedronate Sodium)

Risedronate sodium binds to hydroxyapatite crystals on bone surfaces undergoing active remodeling. When osteoclasts ingest the bound drug, it inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, reducing osteoclast activity and thereby decreasing bone resorption.

The specific dose of Norifaz is determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions and local labeling requirements.

The safety of Norifaz during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To order Norifaz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Norifaz (risedronate) is a nitrogen‑containing bisphosphonate with a potency comparable to alendronate and ibandronate. All share the same basic mechanism of inhibiting osteoclast‑mediated bone resorption, but dosing frequency, renal safety profiles, and specific FDA/EMA approvals may differ among agents.

Norifaz should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture. Keep the product out of direct sunlight and away from excessive heat or humidity to maintain stability.

Norifaz is taken orally, usually with a full glass of water on an empty stomach. Patients should remain upright for at least 30 minutes after ingestion and avoid eating or drinking anything other than water during that time to reduce esophageal irritation.

Serious adverse events associated with Norifaz include osteonecrosis of the jaw, atypical femur fractures, severe esophagitis, and acute hypocalcemia. Patients should report persistent jaw pain, unusual thigh pain, or difficulty swallowing to their healthcare provider promptly.

Norifaz is contraindicated in patients with known hypersensitivity to risedronate or other bisphosphonates, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals with active esophageal disorders that delay esophageal clearance.